Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 1400W. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.61 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.61 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.61 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.61 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.61 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.61 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.61 |
| ▸ | NOS2 | P35228 | 9/20 | 1.00 |
| ▸ | NOS1 | P29475 | 6/20 | 1.00 |
| ▸ | NOS3 | P29474 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1400W SCHEMBL29386443 | 1.00 | NOS2 (1.00) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| 1400W SCHEMBL524310 | 0.98 | NOS2 (1.00) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL9062832 | 0.79 | NOS1 (0.68) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4737504 | 0.79 | NOS2 (0.92) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL29037227 | 0.79 | NOS1 (0.67) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL9063327 | 0.77 | NOS1 (0.64) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL14291059 | 0.77 | NOS2 (0.96) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL20675953 | 0.77 | NOS2 (0.96) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL16378769 | 0.76 | NOS2 (0.63) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6018896 | 0.76 | LOXL2 (0.67) | NOS2NOS1NOS3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD (IL) | 2021-01-14 | — | — | US | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD (IL) | 2021-01-14 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20140243425-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8784870-B2 | Controlled release compositions for modulating free-radical induced damage and methods of use thereof | OTONOMY, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243425-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | GRIN2D 4273/4885GRIN3B 2706/4885GRIN1 2644/4885 |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | GRIN2D 4273/4885GRIN3B 2706/4885GRIN1 2644/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | GRIN2D 4679/4885GRIN3B 3518/4885GRIN1 4171/4885 |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | CNR1, GLRA1, GLRA3 | GRIN2D 56/4885GRIN3B 40/4885GRIN1 18/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | GRIN2D 4679/4885GRIN3B 3518/4885GRIN1 4171/4885 |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | GRIN2D 4587/4885GRIN3B 3399/4885GRIN1 4056/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | GRIN2D 4199/4885GRIN3B 2685/4885GRIN1 4107/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | GRIN2D 3542/4885GRIN3B 2261/4885GRIN1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.